Development of a novel immunoassay to detect interactions with the transactivation domain of p53: application to screening of new drugs
Abstract Tumor protein p53 acts as a trans-activator that negatively regulates cell division by controlling a set of genes required for cell cycle regulation, making it a tumor suppressor in different types of tumors. Because the transcriptional activity of p53 plays an important role in the occurre...
Guardado en:
Autores principales: | Yufeng Xiong, Yingsong Wu, Shuhong Luo, Yang Gao, Yujing Xiong, Daxiang Chen, Hao Deng, Wenbo Hao, Tiancai Liu, Ming Li |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/838d43d4090a434cbc14ccf27143dbda |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
p53 Transactivation Domain Mediates Binding and Phase Separation with Poly-PR/GR
por: Sinem Usluer, et al.
Publicado: (2021) -
Screening of the HBx transactivation domain interacting proteins and the function of interactor Pin1 in HBV replication
por: Qiaoxia Zhou, et al.
Publicado: (2021) -
DIAGNOSTIC ACCURACY OF DRUG SCREENING IMMUNOASSAYS IN DRUG FACILITATED CRIMES
por: Sadia Dawood, et al.
Publicado: (2021) -
p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system.
por: Virginia Andreotti, et al.
Publicado: (2011) -
Dramatically Enhancing the Sensitivity of Immunoassay for Ochratoxin A Detection by Cascade-Amplifying Enzyme Loading
por: Zhuolin Song, et al.
Publicado: (2021)